Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Possible Cross-Reactivity Between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease MESHD and Death MESHD

    Authors: Robert Root-Bernstein

    id:10.20944/preprints202007.0141.v2 Date: 2020-08-04 Source:

    Various studies indicate that vaccination, especially with pneumococcal vaccines, protects against symptomatic cases of SARS-CoV-2 infection MESHD and death MESHD. This paper explores the possibility that pneumococcal vaccines in particular, but perhaps other vaccines as well, contain antigens that might be cross-reactive with SARS-CoV-2 antigens. Comparison of the glycosylation structures of SARS-CoV-2 with the polysaccharide structures of pneumococcal vaccines yielded no obvious similarities. However, while pneumococcal vaccines are primarily composed of capsular polysaccharides, some are conjugated to CRM197, a modified diphtheria MESHD toxin, and all contain about three percent protein contaminants, including the pneumococcal surface proteins PsaA, PspA and probably PspC. All of these proteins have very high degrees of similarity, using very stringent criteria, with several SARS-CoV-2 proteins including the spike protein, membrane protein and replicase 1a. CRM197 is also present in Hib and meningitis MESHD meningitis HP vaccines. Equivalent similarities were found at statistically significantly lower rates, or were completely absent, among the proteins in diphtheria MESHD, tetanus MESHD, pertussis, measles MESHD, mumps MESHD, rubella MESHD, and poliovirus vaccines. Notably, PspA and PspC are highly antigenic and new pneumococcal vaccines based on them are currently in human clinical trials so that their effectiveness against SARS-CoV-2 disease MESHD is easily testable.

    COVID-19 Infected Woman with Tuberculous Meningitis MESHD Meningitis HP: A Case Report

    Authors: Mahshid Nadershahbaz; Reza Bidaki; Saeid Azimi; fatemeh saghafi

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Background: Several factors have been reported for COVID-19 disease MESHD. In addition, patients with COVID-19 are also susceptible to suffer from other problems. In this study, a case suffering from TB meningitis MESHD meningitis HP is reported to have developed COVID-19 disease MESHD, eventually showing symptoms of psychological disorders.Case presentation: A young Afghan woman was hospitalized with TB meningitis MESHD meningitis HP who did not respond to treatment. After a while, she was hospitalized again with diagnosis of COVID-19. The patient showed symptoms of postpartum depression MESHD and anxiety HP. She also had pseudoseizure attacks several times, so antidepressants and anti- anxiety HP medications were started for the patient In order to treat conversion disorder and panic disorders.Conclusion: Tuberculous meningitis MESHD meningitis HP, postpartum depression MESHD and other factors can increase the risk of COVID-19 infection MESHD leading to psychological disorders like conversion disorder in susceptible.

    nCoV-2019 infection MESHD induces neurological outcome and manifestation, linking its historical ancestor SARS-CoV & MERS-CoV: A systematic review and meta-analysis

    Authors: Ajay Prakash; Harvinder Singh; Phulen Sarma; Anusuya Bhattacharyya; Deba Prasad Dhibar; Neeraj Balaini; Ritu Shree; Manoj Goyal; Manish Modi; BIKASH MEDHI

    doi:10.21203/ Date: 2020-06-15 Source: ResearchSquare

    Importance: The first systematic review and meta-analysis to help clinician to identify early the sign and symptoms MESHD of neurological manifestation in COVID-19 positive patients which further help in early management of patients. Objective: Present systematic review and meta-analysis aimed to discuss the prevalence SERO of neurological involvement of the 2019-nCoV patients and assess the symptomatic trend of events as compared to the 2002 “SARS” and 2012 “MERS” pandemics.Methods: The articles were systematically screened through several search engine and databases. The articles published or in preprint were included in the study till 15th May 2020. The systematic review done as per the published literatures which included 31 cross sectional, observational studies and case reports which revealed neural sign and symptoms MESHD in SARS-COV-2 disease MESHD. For meta-analysis, we included 09 observational and cross sectional studies which included COVID-19 positive patients and assessed the predominance of various neurological sign and symptoms MESHD in COVID-19 patients relation to SARS-2002 and MERS-2012. Data were analyzed by using the “MedCalc Statistical Software version 19.2.6 and reported as pooled prevalence SERO. Heterogeneity was investigated (standard I2 test).  Results: We have collected and screened about a total 2615 articles, finally we have included 31 articles for the systematic review and 09 for meta-analysis as per the inclusion/exclusion criteria. The analysis was made as per the prevalence SERO rate of neurological symptoms during the COVID-19 positive patients. The cumulative neurological outcome of SARS-2002 and MERS-2012 was assessed to get the trends which is next tried to correlate the events with the current pandemic. During the analysis severity and outcome of neurological manifestations range from simple headache MESHD headache HP to vague non-focal complaints to severe neurologic impairment associated with seizure MESHD seizure HP or meningitis MESHD meningitis HP.Conclusion & Relevance: Central and peripheral nervous system (CNS/PNS) manifestations were seen during the SARS-2002, MERS-2012 and COVID-19. However, none of the publication found with the primary or secondary objective of finding the neurological manifestation in the COVID-19 patients and their mechanism which strengthen the importance to start more precise clinical trials.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.